Transplant and onco-nephrologist @UAlbertaNeph. @MayoClinic, @UBC and @Queensu alum. Runner. Salt Water Person.

Edmonton
Joined April 2010
Elena-Bianca Barbir, MD retweeted
This is an extraordinary result Teclistamab (CD3 x BCMA bispecific antibody) plus Daratumumab (CD38 antibody) vs. standard care for relapsed or refractory multiple myeloma The future of medicine is very very bright
Unprecedented. #ASH25 Tec-Dara in relapsed myeloma. @mvmateos
17
93
8
548
73,372
American Society of OncoNephrology Upcoming educational activity ✅Journal club: Bio-marker guided Influximab therapy @Arjun_Mohan1 @HerrmannMd @SabineKaram6 ✅December 12th, 12 PM EDT
1
12
1
22
4,781
Elena-Bianca Barbir, MD retweeted
Seeing the light (chains): a paradigm shift in PGNMID - Kidney International kidney-international.org/art… @JeanHouMD #renalpath #PGNMID
25
1
59
6,289
Dr Phil Halloran at CST on what the molecular microscope has taught us so far about kidney allograft rejection - “rejection is a chronic condition not an episode”.
3
169
CAR-T therapy and Lymph node architecture Amazing lecture by @BradRovin on Lupus Nephritis #GlomConHawaii
10
2
28
2,439
We are honored to welcome 🤗 Dr Pierre Ronco as Visiting Professor at @MayoClinicNeph #MedEd Grand Rounds tilted “New advances in immune-mediated podocytopathies: Is anti-nephrin the new anti-PLA2R?” 👩‍🔬 Key Conclusions •🧪 Anti-nephrin antibodies confirmed as correlating with disease activity and likely involved in GCW alterations •🧭 First biomarker available for diagnosis/monitoring in children + adults; may help prevent post-transplant relapses •🧫 ELISA assays for clinical use coming soon (Euroimmun, bridge ELISA for research) •🧩 New concept: Slit diaphragm antigens (nephrin, podocin, NEPH1, NEPH3) drive autoimmune podocytopathies ❓ Key Open Questions •🔮 Can anti-nephrin antibodies predict steroid dependence/resistance? •📈 Is there correlation between antibody levels and outcomes? •🔁 Can they predict relapse? •🧬 What are the antigenic targets in anti-nephrin negative patients (esp. primary FSGS)? •⚠️ Are all anti-nephrin antibodies pathogenic? •🧠 Other permeability factors yet to be found? •⏱ Why is remission so fast after steroids? •🧾 What is the mechanism of immunization? •🕰 Perspective: “18 years after anti-PLA2R discovery, we still do not know everything!”
19
1
36
1,766
🚨 Editor’s Choice 🚨 "The impact of the Banff v-lesion on rejection classification and outcomes: Insights from a multicenter study," by Wellekens et al. amjtransplant.org/article/S1…
2
4
539
I really enjoyed this year’s ASON symposium. Learned lots, reconnected with friends and mentors, and made new friends. Grateful to @HerrmannMd, Dr Nelson Leung, and @LeticiaRolonMD for the invitation. Looking forward to next year’s symposium already! 🥂
5
215
Elena-Bianca Barbir, MD retweeted
Final picture! We would like to thank all the Speakers and Moderators and everyone who attended in person and livestream ! Safe travels back home . @rc_oncneph @LeticiaRolonMD @onconeph @AbdullahJalalMD @MayoClinicNeph @onconephsociety
17
66
2,979
👀 Check out our September Literature Watch, "Location, location, location—How real estate immunity and preservation of self are defined" by Drinkwater et al: amjtransplant.org/article/S1…
2
4
647
Elena-Bianca Barbir, MD retweeted
Membranous nephropathy has undergone a paradigm shift due to the discovery of unique MN antigens. MN has gone from idiopathic to ➡️ primary vs. secondary ➡️ where an antigen can be detected in ~80% of MN. This is a comprehensive review of each antigen. nature.com/articles/s41581-0…
6
88
2
206
15,899
Elena-Bianca Barbir, MD retweeted
1/5 SPLENOMEGALY/HYPERSPLENISM Mechanisms of splenomegaly: • Congestive • Work hypertrophy • Infiltrative What enlarges? • Red pulp: macrophages, sinusoids, blood • White pulp: lymphocytes, plasma cells • Infiltrative: tumor, storage cells, granulomas, amyloid #MedEd
3
106
1
407
38,359
Not all drug related TMA’s are made equal. But for a subset (I.e. VEGFi, Gemcitabine), terminal complement blockade allows continuation of the offending drug, with important implications for progression free survival in the long term.
9
19
2,080
Elena-Bianca Barbir, MD retweeted
Baffling: PGNMID, monoclonal no more I got this consult case as immune complex-MPGN LM- MPGN pattern IF- IgG, C3, C1q, kappa & lambda 3+ Did IgG subtypes-IgG3 3+, all others negative EM- mottled deposits Dx- Proliferative GN, IgG3, but ? with monoclonal IgG deposits (PGNMID)
7
33
103
7,951
Elena-Bianca Barbir, MD retweeted
Don't miss this @MayoClinicNeph conference! Onco-Nephrology Symposium will cover nephrotoxicity of chemotherapeutic agents, patients with dialysis-dependent end-stage renal disease, & much more. Register for Sept. 11-12 in Minnesota & via livestream. ce.mayo.edu/nephrology/conte…
5
9
879
Elena-Bianca Barbir, MD retweeted
IgM Variant of Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits: A Case Series bit.ly/3Ec18Od #OpenAccess @Bhanu2405 @SethiRenalPath #VisualAbstract
1
25
65
4,434
Elena-Bianca Barbir, MD retweeted
Viewpoint discusses how "skimming the median" can exaggerate survival gains in clinical trials, underscoring the need to critically evaluate Kaplan-Meier curves alongside hazard ratios. ja.ma/45mitxx
3
50
3
136
15,817